24 / 38
Single centre experience: PFS and OS of nal-IRI+5-FU/LV,
stratified by prior non-liposomal irinotecan treatment
HR, hazard ratio; IRI, non-liposomal irinotecan; mo, months; mOS,
median overall survival; mPFS, median progression-free survival
Glassman DC, et al. J Clin Oncol 2018;
36 (suppl 4S): 471 (and poster)
100
0
50
Survival probability
Months
0
5
10
20
15
100
0
50
Survival probability
Months
0
5
10
20
15
PFS
OS
Log-rank test (p)
HR (log-rank)
Log-rank test (p)
HR (log-rank)
IRI, no progression vs. IRI, progression
0.041
0.41 (0.19–0.86)
0.035
0.31 (0.13–0.70)
No prior IRI vs. IRI, progression
0.022
0.51 (0.28–0.93)
0.0021
0.38 (0.20–0.72)
mPFS (mo)
mOS (mo)
Prior IRI without progression (n = 6)
5.71
9.01
Prior IRI with progression (n = 27)
2.24
3.91
No prior IRI (n = 23)
4.57
7.7
PFS of nal-IRI+5-FU/LV by prior
non-liposomal irinotecan treatment
OS of nal-IRI+5-FU/LV by prior
non-liposomal irinotecan treatment